United Therapeutics (UTHR) Stock Price, News & Analysis

Company Overview

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Key Stats

• Today's Range: $284.39 to $286.29
• 50-Day Range: $276.47 to $328.40
• 52-Week Range: $250.60 to $417.82
• Volume: 16,171 shs
• Average Volume: 444,465 shs
• Market Capitalization: $13.01 billion
• P/E Ratio: 11.51
• Dividend Yield: N/A
• Price Target: $393.08
• Consensus Rating: Moderate Buy

United Therapeutics Stock Analysis - MarketRank™

United Therapeutics scored higher than 100% of companies evaluated by MarketBeat, and ranked 5th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

United Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

United Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.30%

Earnings Growth

Earnings for United Therapeutics are expected to grow by 12.30% in the coming year, from $24.48 to $27.49 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of United Therapeutics is 11.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.88.

Price to Earnings Ratio vs. Sector

The P/E ratio of United Therapeutics is 11.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.28.

Price to Earnings Growth Ratio

United Therapeutics has a PEG Ratio of 6.22. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

United Therapeutics has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.66% of the float of United Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

United Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in United Therapeutics has recently decreased by 14.36%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

United Therapeutics does not currently pay a dividend.

Dividend Growth

United Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -2.00

Percentage of Shares Shorted

3.66% of the float of United Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

United Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in United Therapeutics has recently decreased by 14.36%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.95

News Sentiment

United Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for United Therapeutics this week, compared to 14 articles on an average week.

Search Interest

4 people have searched for UTHR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,319,919.00 in company stock.

Percentage Held by Insiders

10.30% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

UTHR Stock Analysis - Frequently Asked Questions

How have UTHR shares performed this year?

United Therapeutics' stock was trading at $352.84 on January 1st, 2025. Since then, UTHR stock has decreased by 19.0% and is now trading at $285.6950.
View the best growth stocks for 2025 here.

How were United Therapeutics' earnings last quarter?

United Therapeutics Corporation (NASDAQ:UTHR) released its quarterly earnings results on Wednesday, April, 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping the consensus estimate of $6.29 by $0.34. The company's revenue for the quarter was up 17.2% on a year-over-year basis.
Read the conference call transcript.

How do I buy shares of United Therapeutics?

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that United Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 4/30/2025
• Today: 6/30/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:UTHR
• CIK: 1082554
• Web: www.unither.com
• Phone: (301) 608-9292
• Fax: 301-608-9291
• Employees: 1,305
• Year Founded: 1996

Price Target and Rating

• Average Stock Price Target: $393.08
• High Stock Price Target: $600.00
• Low Stock Price Target: $302.00
• Potential Upside/Downside: +38.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.69
• Research Coverage: 13 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $25.06
• Trailing P/E Ratio: 11.34
• Forward P/E Ratio: 11.61
• P/E Growth: 6.22
• Net Income: $1.20 billion
• Net Margins: 40.44%
• Pretax Margin: 52.23%
• Return on Equity: 19.33%
• Return on Assets: 16.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.46
• Quick Ratio: 5.23

Sales & Book Value

• Annual Sales: $2.88 billion
• Price / Sales: 4.46
• Cash Flow: $28.40 per share
• Price / Cash Flow: 10.01
• Book Value: $144.34 per share
• Price / Book: 1.97

Miscellaneous

• Outstanding Shares: 45,110,000
• Free Float: 40,461,000
• Market Cap: $12.82 billion
• Optionable: Optionable
• Beta: 0.57